AstraZeneca names new non-executive directors By Investing.com
AstraZeneca names new non-executive directors…
60,750€
0,41%
Echtzeit-Aktienkurs Astrazeneca PLC (Spons. ADRs)
Bid:
Ask:
Nachrichten zur Astrazeneca PLC (Spons. ADRs) Aktie
Could IonQ Be Your Ticket to Becoming a Millionaire by 2035?
Finding a company that can make you a millionaire from a modest investment is rare. However, they are out there…
3 Unstoppable Stocks to Buy Right Now
Some stocks sizzle, then fizzle. Others, though, build long-lasting momentum thanks to strong underlying business fundamentals. Three Motley Fool contributors…
AstraZeneca (AZN) Shares Fall After Reports of PRC Probe Alleged Fraud and Corruption – Hagens Berman
SAN FRANCISCO, Dec. 11, 2024 (GLOBE NEWSWIRE) -- AstraZeneca PLC (NASDAQ: AZN) is facing a significant crisis in…
50 Companies to Watch in 2025
From AstraZeneca to Vodacom, keep an eye on these global stocks this year.…
Better Quantum Computing Stock: Rigetti Computing vs. IonQ, Inc.
The quantum computing industry has emerged as one of 2024s hottest investing themes, with leading players seeing their stocks surge…
AZN, Daiichis ADC Gets FDA Breakthrough Tag for EGFR-Mutated NSCLC
The FDA bestows a Breakthrough Therapy designation to AstraZeneca and Daiichi Sankyos Dato-DXd for previously treated advanced EGFR-mutated NSCLC.…
2 No-Brainer Dividend Stocks With Yields Over 3% to Buy in 2025 and Hold for a Decade or Longer
Whether youre looking for a way to beat the benchmark S&P 500 index or you just want a steady flow…
Imfinzi approved in US for limited-stage SCLC
5 December 2024
Imfinzi approved in the US as first and only immunotherapy
regimen for patients with limited-stage small cell lung cancer
Based on…
AstraZenecas Imfinzi Gets FDA Nod for Expanded Use in SCLC
The FDA approves AZNs Imfinzi for treating patients with limited-stage small-cell lung cancer based on phase III ADRIATIC study data.…